Tarsus Pharmaceuticals Chief Medical Officer Lin Elizabeth Yeu sold 11,578 shares in three transactions priced from $73.86 to $80 per share. For investors, the disclosure also identifies Yeu’s post-sale holding at 4,770 shares, showing the stake that remained after the reported transactions.
Key Highlights
- The transactions occurred between September 1 and September 2.
- Lin Elizabeth Yeu owned 4,770 shares after the transactions.
- Each reported transaction carried sales code S.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) Chief Medical Officer Lin Elizabeth Yeu sold 11,578 shares across three transactions at prices ranging from $73.86 to $80 per share. The transactions took place between September 1 and September 2.
Yeu’s Remaining Tarsus Stake
Yeu held 4,770 shares after completing the transactions. The reported activity consisted of three separate sales, each identified with transaction code S. Lin Elizabeth Yeu serves as Tarsus Pharmaceuticals’ Chief Medical Officer. The transactions covered the stated price range of $73.86 to $80 per share.
FAQs
Q: How many Tarsus Pharmaceuticals shares did Lin Elizabeth Yeu sell?
A: Lin Elizabeth Yeu sold 11,578 Tarsus Pharmaceuticals shares. The sales occurred across three transactions priced between $73.86 and $80 per share.
Q: How many Tarsus Pharmaceuticals shares did Yeu own afterward?
A: Lin Elizabeth Yeu owned 4,770 Tarsus Pharmaceuticals shares after the transactions. The remaining holding was reported following the completed sales.
Q: When did the Tarsus Pharmaceuticals share sales occur?
A: The Tarsus Pharmaceuticals transactions took place between September 1 and September 2. Each transaction was recorded under sales code S.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.